A FAERS database analysis identified 13 FDA-approved systemic medications with disproportionately high uveitis reporting signals among 7,301 events from 2003 to 2024. The strongest signals were for cidofovir and rifabutin, and the findings were described as hypothesis-generating rather than causal.
Hanmi Pharmaceutical has initiated phase 2 patient dosing of belvarafenib for NRAS-mutated melanoma in Korea, enrolling the first patient at a university hospital. The multicenter trial will evaluate combination therapy in 45 patients with locally advanced or metastatic disease.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06813079 |
Using Tumor Models to Determine Treatments |
RECRUITING | PHASE2 |
| NCT05691504 |
Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers |
ACTIVE_NOT_RECRUITING | PHASE1 |
| NCT05441514 |
Enasidenib in Combination With Cobimetinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia |
COMPLETED | PHASE1 |
| NCT05034627 |
Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer |
COMPLETED | PHASE1 |
| NCT04931342 |
A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT04835805 |
A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma. |
ACTIVE_NOT_RECRUITING | PHASE1 |
| NCT04409639 |
Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway Mutations |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT04302025 |
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC) |
RECRUITING | PHASE2 |
| NCT04216953 |
MEK Inhibitor and a PDL1 Inhibitor Patients With Locally Advanced and/or Metastatic Soft Tissue Sarcoma |
COMPLETED | PHASE1/PHASE2 |
| NCT03768063 |
A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study |
ACTIVE_NOT_RECRUITING | PHASE3 |
